Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.762332
Title: Generation of MHC class I allospecific regulatory T cells using chimeric antigen receptors, tools for eliciting targeted transplant tolerance
Author: Boardman, Dominic Anthony
ISNI:       0000 0004 7656 3176
Awarding Body: King's College London
Current Institution: King's College London (University of London)
Date of Award: 2017
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Regulatory T cells (Treg) therapy using autologous Tregs expanded ex vivo is currently being assessed clinically as a means of limiting graft rejection. However, pre-clinical data has demonstrated that graft-specific Tregs protect from graft rejection more effectively than polyclonal Tregs. Chimeric antigen receptor (CAR) technology is currently being investigated clinically as a means of conferring tumour antigen-specificity onto T cells in cancer research. CARs are synthetic fusion proteins which translate the engagement of extracellular target antigens into the activation of intracellular T cell signalling cascades. The hypothesis tested in this thesis was that the efficacy of polyclonal Treg therapy to inhibit transplant rejection could be enhanced by using CARs to confer specificity for donor MHC class I, alloantigens which are ubiquitously expressed in allografts. A human CAR was constructed to incorporate a patient-derived HLA-A2-targeting moiety and a CD28-CD3ζ signalling domain. Delivery of this CAR into human Tregs which were isolated using GMP-compatible protocols did not influence the phenotype or suppressive capacity of these cells. Compared to polyclonal Tregs, A2 CAR Tregs exhibited a greater suppressive function in the presence of HLA-A2+ antigen presenting cells, without eliciting cytotoxic activity. Furthermore, these cells preferentially transmigrated across HLA-A2-expressing endothelial cell monolayers, suggesting a favoured migration in to HLA-A2+ target tissues. In a human skin xenograft transplant model, A2 CAR Tregs alleviated alloimmune-mediated damage of HLA-A2+ skin more effectively than polyclonal Tregs. A second CAR was designed to redirect mouse Tregs towards BALB/c MHC class I (Kd) with the rationale of comparing the efficacy of CAR Tregs and Tregs with different allospecificities at reducing graft rejection. Murine CAR Tregs maintained their phenotype and suppressive ability and appeared to proliferate in the presence of Kd in vivo although conclusive evidence for the functionality of this CAR remained to be acquired. The results obtained demonstrated that CARs can be used to generate MHC class I-allospecific Tregs which are functionally superior to polyclonal Tregs at protecting from alloimmune-mediated transplant rejection, suggesting that CAR technology is a clinically applicable refinement of Treg therapy for organ transplantation.
Supervisor: Lombardi, Giovanna ; Smith, Sandra Lesley ; Maher, John Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.762332  DOI: Not available
Share: